SCHEMBL19687799

SCHEMBL19687799

CC(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN)C(C)C)cc1

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 11/20 0.42
SIRT1 Q96EB6 10/20 0.42
ROCK2 O75116 1/20 0.42
SIRT3 Q9NTG7 6/20 0.42
NPY1R P25929 3/20 0.42
NPY4R P50391 3/20 0.42
NPY5R Q15761 3/20 0.42
NPY2R P49146 2/20 0.42
SIRT5 Q9NXA8 1/20 0.41
FURIN P09958 1/20 0.40
NMT2 O60551 1/20 0.40
NMT1 P30419 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19687798 1.00 SIRT2 (0.42) SIRT2SIRT1ROCK2SIRT3NPY1R
SCHEMBL21152791 0.94 SIRT2 (0.49) SIRT2SIRT1SIRT3
SCHEMBL21152621 0.94 SIRT2 (0.43) SIRT2SIRT1SIRT3NPY1RNPY4R
SCHEMBL16156452 0.94 SIRT2 (0.42) SIRT2SIRT1ROCK2SIRT3NPY1R
SCHEMBL14887361 0.93 SIRT2 (0.42) SIRT2SIRT1ROCK2SIRT3NPY1R
SCHEMBL20153097 0.93 SIRT5 (0.41) SIRT2SIRT1SIRT3NPY1RNPY4R
SCHEMBL15606204 0.93 SIRT2 (0.41) SIRT2SIRT1ROCK2SIRT3NPY1R
SCHEMBL18758412 0.93 SIRT5 (0.42) SIRT2SIRT1SIRT3NPY1RNPY4R
SCHEMBL25094717 0.92 SIRT2 (0.42) SIRT2SIRT1ROCK2SIRT3NPY1R
SCHEMBL22643617 0.92 SIRT2 (0.42) SIRT2SIRT1ROCK2SIRT3NPY1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210106690-A1 PROTEIN-POLYMER-DRUG CONJUGATES MERSANA THERAPEUTICS, INC. 2021-04-15 US disclosed
US-10603386-B2 Protein-polymer-drug conjugates MERSANA THERAPEUTICS, INC. (US) 2020-03-31 US disclosed
US-20180140716-A1 PROTEIN-POLYMER-DRUG CONJUGATES MERSANA THERAPEUTICS, INC. 2018-05-24 US disclosed
US-20170348424-A1 PROTEIN-POLYMER-DRUG CONJUGATES MERSANA THERAPEUTICS, INC. 2017-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348424-A1 PROTEIN-POLYMER-DRUG CONJUGATES PBRM1, CLTB, BRAP SIRT2 2534/4885SIRT1 2369/4885ROCK2 3947/4885
US-20180140716-A1 PROTEIN-POLYMER-DRUG CONJUGATES PBRM1, STAMBP, TSPO SIRT2 2841/4885SIRT1 2541/4885ROCK2 2810/4885
US-20210106690-A1 PROTEIN-POLYMER-DRUG CONJUGATES PBRM1, CLTB, BRAP SIRT2 2205/4885SIRT1 1989/4885ROCK2 3812/4885
US-10603386-B2 Protein-polymer-drug conjugates PBRM1, CLTB, BRAP SIRT2 2262/4885SIRT1 2098/4885ROCK2 3917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.